미국의 조직 진단 시장 규모, 점유율, 동향 분석 보고서 : 기술 및 제품별, 용도별, 지역별, 부문별 예측(2025-2030년)

U.S. Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology & Product (IHC, Primary & Special Staining), By Application (Breast Cancer, NSCLC), And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

미국의 조직 진단 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 미국의 조직 진단 시장 규모는 2030년까지 44억 달러에 달할 것으로 예상되며, 2025-2030년 연평균 8.3%의 CAGR을 기록할 것으로 추정됩니다. 시장 성장을 보완하는 중요한 요인으로는 암 환자의 지속적인 증가, 장기 이식 및 장기 기증의 증가, 미국 내 맞춤형 의료 및 동반진단에 대한 수용성 증가 등이 있습니다.

해부병리학 부문은 미국 내 암 발병률의 급격한 증가로 인해 패러다임의 변화를 목격하고 있습니다. 또한, 분자 병리학과 해부학적 병리학의 꾸준한 융합, 암 검출을 위한 새로운 생검법의 빠른 채택, 디지털 기술의 통합이 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다.

조직 분석은 기존의 분자 기술로는 이해하기 어려운 중요한 정보를 담고 있습니다. 현재, 동반진단 검사는 제약회사들이 자사 제품의 1차 치료제 지정/승인을 획득하기 위해 빠르게 채택되고 있습니다. 또한, 표적 치료의 효과가 기대되는 환자 코호트를 식별하는 데 사용되면서 정밀 의약품 개발에서 조직 진단의 중요성이 커지고 있습니다.

또한, 조직 진단 부문은 형광 현장 하이브리드화(FISH), 면역조직화학(IHC), 면역형광(IF), 비교 유전체 하이브리드화, 차세대 염기서열 분석(NGS) 등 업그레이드된 기술을 채택하여 점차 진화하고 있습니다. 주요 기업들은 새로운 바이오마커 발굴과 첨단 암 진단을 위한 분석법 개발에 집중하고 있습니다. 또한, 각 업체들은 최신 병리학적 솔루션의 채택률을 높이기 위해 바이오마커 병리학자 교육 프로그램을 시행하고 있습니다.

미국의 조직 진단 시장 보고서 하이라이트

• 기술 및 제품별로는 면역조직화학 부문이 2024년 27.74%의 최대 매출 점유율로 시장을 주도했습니니다.
• 용도별로는 유방암 부문이 2024년 50.45%의 최대 매출 점유율로 시장을 주도했습니니다. 조직 진단은 환자의 유방암을 평가하는 데 중요한 역할을 합니다.
• 최종 용도별로는 병원 부문이 2024년 37.82%의 최대 매출 점유율로 시장을 주도했습니다. 병원 및 클리닉에서 조직 진단 시스템 및 서비스의 사용은 매년 증가하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 미국의 조직 진단 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 미국의 조직 진단 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 미국의 조직 진단 시장 : 기술·제품별, 추정·동향 분석

• 부문 대시보드
• 미국의 조직 진단 시장 : 기술·제품 변동 분석
• 미국의 조직 진단 시장 : 기술·제품 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 면역조직화학
  • 기기
  • 소모품
• ISH(In Situ Hybridization)
  • 기기
  • 소모품
  • 소프트웨어
• 1차 염색과 특수 염색
  • H&E 염색
  • 특수 염색
• 디지털 병리학과 워크플로우
  • 슬라이드 전체의 이미징
  • 이미지 분석 정보학
  • 정보 관리 시스템 보관과 통신
• 해부 병리학
  • 기기
  • 소모품

제5장 미국의 조직 진단 시장 : 용도별, 추정·동향 분석

• 부문 대시보드
• 미국의 조직 진단 시장 : 용도 변동 분석
• 미국의 조직 진단 시장 : 용도 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 유방암
• 비소세포폐암
• 전립선암
• 위암
• 기타 암

제6장 미국의 조직 진단 시장 : 최종 용도별, 추정·동향 분석

• 부문 대시보드
• 미국의 조직 진단 시장 : 최종 용도 변동 분석
• 최종 용도별 미국의 조직 진단 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
• 병원
• 실험실
• 제약 단체
• 최고 경영 책임자

제7장 경쟁 구도

• 시장 진출 기업 분류
• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업 시장 점유율 분석, 2024년
• 주요 기업 개요
  • Merck KGaA
  • Thermo Fisher Scientific, Inc
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher
  • bioMerieux SA
  • QIAGEN
  • Becton, Dickinson &Company(BD)
  • Agilent Technologies, Inc
  • General Electric Company
  • BioGenex
  • Cell Signaling Technology, Inc
  • Bio SB
  • DiaGenic ASA
  • Sakura Finetek Japan Co., Ltd
  • Abcam plc
  • Enzo Life Sciences, Inc
  • VITRO SA(Master Diagnostica)
  • TissueGnostics GmbH

ksm

영문 목차

영문목차

U.S. Tissue Diagnostics Market Growth & Trends:

The U.S. tissue diagnostics market size is estimated to reach USD 4.40 billion by 2030, registering a CAGR of 8.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Pivotal factors supplementing the market growth include continuous rise in the cases of cancer, growth in organ transplantation & donation, and increased acceptance toward personalized medicine & companion diagnostics in the U.S. Increase in the number of research activities targeted toward the development of novel tissue diagnostics solutions is also expected to drive the market.

The field of anatomic pathology has witnessed a paradigm shift, which can be attributed to the exponential growth in cancer incidence in the U.S., thereby expanding the clinical pathology industry. Also, steady convergence of molecular pathology with anatomic pathology, steep adoption of novel biopsies for cancer detection, and integration of digital technologies is expected to collaboratively make a positive impact on market growth.

Tissue analysis provides significant information, which is difficult to understand using conventional molecular techniques. Currently, companion diagnostic tests are rapidly being adopted by pharmaceutical companies for obtaining first-line therapy designations/approvals for their products. In addition, their use in the identification of patient cohorts, which are likely to benefit from targeted therapeutics, has increased the significance of tissue diagnostics in the development of precision medicine.

In addition, the field of tissue diagnostics has witnessed gradual evolution with the introduction of upgraded technologies, including Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Immunofluorescence (IF), comparative genomic hybridization, and Next-Generation Sequencing (NGS). Key players are focused on identifying novel biomarkers and developing assays for advanced cancer diagnosis. Furthermore, companies are conducting biomarker pathologist training programs to boost the adoption rate of modern pathological solutions.

U.S. Tissue Diagnostics Market Report Highlights:

• Based on technology & product, the immunohistochemistry segment led the market with the largest revenue share of 27.74% in 2024.
• Based on application, the breast cancer segment led the market with the largest revenue share of 50.45% in 2024. Tissue diagnostics play a vital role in assessing breast cancer in patients.
• Based on end use, the hospitals segment led the market with the largest revenue share of 37.82% in 2024. The usage of tissue diagnostic systems and services in hospitals & clinics has increased over the years.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology & Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional Scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. U.S. Tissue Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Emerging solutions pertaining to digital tissue diagnostics
    • 3.2.1.2. Advancements in imaging techniques and increasing affordability of diagnostics
    • 3.2.1.3. Growth of personalized therapeutics and diagnostics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of non-value-based reimbursement policy and high costs associated with usage of tissue diagnosis
• 3.3. U.S. Tissue Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. U.S. Tissue Diagnostics Market: Technology & Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Tissue Diagnostics Market: Technology & Product Movement Analysis
• 4.3. U.S. Tissue Diagnostics Market by Technology & Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Immunohistochemistry
  • 4.5.1. Immunohistochemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Instruments
    • 4.5.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.2. Slide Staining Systems
      • 4.5.2.2.1. Slide Staining Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.3. Tissue Microarrays
      • 4.5.2.3.1. Immunohistochemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.4. Tissue Processing Systems
      • 4.5.2.4.1. Tissue Processing Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.5. Slide Scanners
      • 4.5.2.5.1. Slide Scanners Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2.6. Other Products
      • 4.5.2.6.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Consumables
    • 4.5.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3.2. Reagents
      • 4.5.3.2.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3.3. Antibodies
      • 4.5.3.3.1. Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. In situ Hybridization
  • 4.6.1. In situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Instruments
    • 4.6.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Consumables
    • 4.6.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Software
    • 4.6.4.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Primary & Special Staining
  • 4.7.1. Primary & Special Staining Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.2. H&E Staining
    • 4.7.2.1. H&E Staining Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.3. Special Staining
    • 4.7.3.1. Special Staining Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Digital Pathology and Workflow
  • 4.8.1. Digital Pathology and Workflow Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8.2. Whole Slide Imaging
    • 4.8.2.1. Whole Slide Imaging Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8.3. Image Analysis Informatics
    • 4.8.3.1. Image Analysis Informatics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8.4. Information Management System Storage & Communication
    • 4.8.4.1. Information Management System Storage & Communication Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Anatomic Pathology
  • 4.9.1. Anatomic Pathology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9.2. Instruments
    • 4.9.2.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.2. Microtomes & Cryostat Microtomes
      • 4.9.2.2.1. Microtomes & Cryostat Microtomes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.3. Tissue Processors
      • 4.9.2.3.1. Tissue Processors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.4. Automatic Strainers
      • 4.9.2.4.1. Automatic Strainers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.2.5. Other Products
      • 4.9.2.5.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9.3. Consumables
    • 4.9.3.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.3.2. Reagents & Antibodies
      • 4.9.3.2.1. Reagents & Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.3.3. Probes & Kits
      • 4.9.3.3.1. Probes & Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.9.3.4. Others
      • 4.9.3.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Tissue Diagnostics Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Tissue Diagnostics Market: Application Movement Analysis
• 5.3. U.S. Tissue Diagnostics Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Breast Cancer
  • 5.5.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Non-Small Cell Lung Cancer
  • 5.6.1. Non-Small Cell Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Prostate Cancer
  • 5.7.1. Prostate Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Gastric Cancer
  • 5.8.1. Gastric Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Other Cancers
  • 5.9.1. Other Cancers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Tissue Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Tissue Diagnostics Market: End Use Movement Analysis
• 6.3. U.S. Tissue Diagnostics Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Research Laboratories
  • 6.6.1. Research Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Pharmaceutical Organizations
  • 6.7.1. Pharmaceutical Organizations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. CRO
  • 6.8.1. CRO Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2024
• 7.4. Key Company Profiles
  • 7.4.1. Merck KGaA
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Thermo Fisher Scientific, Inc
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. F. Hoffmann-La Roche Ltd
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Abbott Laboratories
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Siemens Healthineers AG
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Danaher
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. bioMerieux SA
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. QIAGEN
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Becton, Dickinson & Company (BD)
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Agilent Technologies, Inc
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. General Electric Company
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. BioGenex
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. Cell Signaling Technology, Inc
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Product benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. Bio SB
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Product benchmarking
    • 7.4.14.4. Strategic initiatives
  • 7.4.15. DiaGenic ASA
    • 7.4.15.1. Company overview
    • 7.4.15.2. Financial performance
    • 7.4.15.3. Product benchmarking
    • 7.4.15.4. Strategic initiatives
  • 7.4.16. Sakura Finetek Japan Co., Ltd
    • 7.4.16.1. Company overview
    • 7.4.16.2. Financial performance
    • 7.4.16.3. Product benchmarking
    • 7.4.16.4. Strategic initiatives
  • 7.4.17. Abcam plc
    • 7.4.17.1. Company overview
    • 7.4.17.2. Financial performance
    • 7.4.17.3. Product benchmarking
    • 7.4.17.4. Strategic initiatives
  • 7.4.18. Enzo Life Sciences, Inc
    • 7.4.18.1. Company overview
    • 7.4.18.2. Financial performance
    • 7.4.18.3. Product benchmarking
    • 7.4.18.4. Strategic initiatives
  • 7.4.19. VITRO SA (Master Diagnostica)
    • 7.4.19.1. Company overview
    • 7.4.19.2. Financial performance
    • 7.4.19.3. Product benchmarking
    • 7.4.19.4. Strategic initiatives
  • 7.4.20. TissueGnostics GmbH
    • 7.4.20.1. Company overview
    • 7.4.20.2. Financial performance
    • 7.4.20.3. Product benchmarking
    • 7.4.20.4. Strategic initiatives

관련자료